

BOOSTRIX™

Combined diphtheria-tetanus-acellular pertussis (dTpa) vaccine

DESCRIPTION

BOOSTRIX™ dTpa vaccine is a sterile suspension which contains diphtheria toxoid, tetanus toxoid and three purified antigens of *Bordetella pertussis* [pertussis toxoid (PT), pertussis filamentous haemagglutinin (FHA) and pertussis 69 kilodalton (kDa) outer membrane protein (OMP)] adsorbed onto aluminium salts.

BOOSTRIX® is a turbid white suspension for injection.

1 dose (0.5 ml) contains:

Diphtheria toxoid¹ not less than 2 International Units (IU) (2.5 Lf)

Tetanus toxoid¹ not less than 20 International Units (IU) (5 Lf)

Bordetella pertussis antigens

Pertussis toxoid¹ 8 micrograms

Filamentous Haemagglutinin¹ 8 micrograms

Pertactin¹ 2.5 micrograms

¹ adsorbed on aluminium hydroxide, hydrated (Al(OH)₃) 0.3 milligrams Al³⁺
and aluminium phosphate (AlPO₄) 0.2 milligrams Al³⁺

The diphtheria toxoid, tetanus toxoid and acellular pertussis vaccine (dTpa) components are adsorbed on 0.5mg aluminium in the form of aluminium hydroxide and aluminium phosphate, and suspended in isotonic sodium chloride. The vaccine preparation also contains 2-phenoxyethanol as a preservative and formaldehyde, polysorbate 80 and glycine in residual amounts.

CLINICAL PHARMACOLOGY

BOOSTRIX™ (dTpa vaccine), induces antibodies against all vaccine components.

Clinical Trials

Immune response results to the diphtheria, tetanus and acellular pertussis components in clinical studies are presented in the table below. Approximately one month following booster vaccination with BOOSTRIX®, the following seroprotection / seropositivity rates were observed:

Antigen	Seroprotection / Seropositivity	Adults and adolescents from the age of 10 years onwards, at least 1690	Children from 4 to 9 years of age, at least 415 subjects (% vaccinees)
---------	---------------------------------	--	--

		subjects (% vaccinees)	
Diphtheria	≥ 0.1 IU/ml*	97.2%	99.8%
Tetanus	≥ 0.1 IU/ml*	99.0%	100.0%
Pertussis:			
- Pertussis toxoid	≥ 5 EL.U/ml	97.8%	99.0%
- Filamentous haemagglutinin	≥ 5 EL.U/ml	99.9%	100.0%
- Pertactin	≥ 5 EL.U/ml	99.4%	99.8%

*cut-off accepted as indicative of protection

Results of the comparative studies with commercial dT vaccines indicates that the degree and duration of protection would not be different from those obtained with these vaccines.

Protective efficacy of pertussis

There is currently no correlate of protection defined for pertussis; however, the protective efficacy of SmithKline Beecham Biologicals' DTPa (INFANRIX™) vaccine against WHO-defined typical pertussis (≥ 21 days of paroxysmal cough with laboratory confirmation) was demonstrated in the following 3-dose primary studies:

- a prospective blinded household contact study performed in Germany (3, 4, 5 months schedule) based on data collected from secondary contacts in households where there was an index case with typical pertussis, the protective efficacy of the vaccine was 88.7%. Protection against laboratory confirmed mild disease, defined as 14 days or more of cough of any type was 73% and 67% when defined as 7 days or more of cough of any type; and
- an NIH sponsored efficacy study performed in Italy (2, 4, 6 months schedule).

The vaccine efficacy was found to be 84%. When the definition of pertussis was expanded to include clinically milder cases with respect to type and duration of cough, the efficacy of INFANRIX™ was calculated to be 71% against >7 days of any cough and 73% against >14 days of any cough. In a follow-up of the same cohort, the efficacy was confirmed up to 5 years after completion of primary vaccination without administration of a booster dose of pertussis.

The study assessed duration of protection of Infanrix given in a 3 dose schedule to infants. A similar duration of protection cannot be assumed to apply to older children or adults given a single dose of BOOSTRIX™, regardless of previous vaccination against pertussis.

Although the protective efficacy of BOOSTRIX™ has not been demonstrated in adolescents and adult age groups, vaccinees in these age groups who received BOOSTRIX™ achieved anti-pertussis antibody titres greater than those in the German household contact study where the protective efficacy of INFANRIX™ was 88.7%.

There are currently no data which demonstrate a reduction of transmission of pertussis after immunisation with BOOSTRIX™. However, it could be expected that immunisation of immediate close contacts of newborn infants, such as parents, grandparents, healthcare workers and childcare workers would reduce exposure of pertussis to infants not yet adequately protected through immunisation.

Persistence of immunity to diphtheria, tetanus and pertussis after vaccination with BOOSTRIX® in children, adolescents and adults

The following seroprotection / seropositivity rates were observed 3 to 3.5 years, 5 to 6 years and 10 years following vaccination with BOOSTRIX®:

Antigen	Seroprotection/ seropositivity	Adults and adolescents from the age of 10 years onwards (% vaccinees)						Children from the age of 4 years onwards (% vaccinees)	
		3-3.5 years persistence		5 years persistence		10 years persistence		3-3.5 years persistence	5 to 6 years persistence
		Adult	Adole- scent	Adult	Adole- scent	Adult	Adole- scent		
Diphtheria	≥ 0.1 IU/ml*	71.2%	91.6%	84.1%	86.8%	64.6%	82.4%	97.5 %	94.2 %
	≥ 0.016 IU/ml*	97.4%	100%	94.4%	99.2%	89.9%	98.6%	100 %	Not determined
Tetanus	≥ 0.1 IU/ml	94.8%	100%	96.2%	100%	95.0%	97.3%	98.4 %	98.5 %
Pertussis Pertussis toxoid	≥ 5 EL.U/ml	90.6%	81.6%	89.5%	76.8%	85.6%	61.3%	58.7 %	51.5 %
Filamentous haemaggluti nin		100%	100%	100%	100%	99.4%	100%	100 %	100 %
Pertactin		94.8%	99.2%	95.0%	98.1%	95.0%	96.0%	99.2 %	100 %

* Percentage of subjects with antibody concentrations associated with protection against disease (≥ 0.1 IU/ml by ELISA assay or ≥ 0.016 IU/ml by an in-vitro Vero-cell neutralisation assay).

BOOSTRIX® administered in subjects ≥40 years of age with an incomplete, unknown or no history of a primary series of diphtheria and tetanus toxoid vaccination history induced an antibody response against pertussis in more than 98.5% of adults and provided seroprotection against diphtheria and tetanus in 81.5% and 93.4% of adults respectively.

Two subsequent doses maximised the vaccine response against diphtheria and tetanus when administered at one and six months (99.3% and 100% respectively).

Vaccination with second dose of BOOSTRIX®

The immunogenicity of BOOSTRIX®, administered 10 years after a previous booster dose with BOOSTRIX® or reduced-antigen content diphtheria, tetanus and acellular pertussis vaccines has been evaluated in adults. One month after the decennial BOOSTRIX® dose, ≥99 % of subjects were seroprotected against diphtheria and tetanus and all were seropositive for antibodies against pertussis antigens PT, FHA and PRN.

INDICATIONS

BOOSTRIX™ is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals aged ten years and older.

CONTRAINDICATIONS

BOOSTRIX™ should not be administered to subjects with known hypersensitivity to any component of the vaccine, or to subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus or pertussis vaccines.

As with other vaccines, the administration of BOOSTRIX™ should be postponed in subjects suffering from acute severe febrile illness. The presence of a minor infection, however, is not a contraindication.

BOOSTRIX™ is contra-indicated if the subject has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis-containing vaccine. In these circumstances, pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria and tetanus vaccines.

BOOSTRIX™ should not be administered to subjects who have experienced transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus (for convulsions or hypotonic-hyporesponsive episodes, see PRECAUTIONS).

PRECAUTIONS

BOOSTRIX should under no circumstances be administered intravenously.

It is good clinical practice that immunisation should be preceded by a review of the medical history (especially with regard to previous immunisation and possible occurrence of undesirable events) and a clinical examination.

If any of the following events have occurred in temporal relation to receipt of pertussis containing vaccines, the decision to give doses of pertussis containing vaccines, should be carefully considered.

There may be circumstances, such as a high incidence of pertussis, when the potential benefits outweigh possible risks, particularly since these events are not associated with permanent sequelae.

- Temperature of $\geq 40.0^{\circ}\text{C}$ within 48 hours of vaccination, not due to another identifiable cause.
- Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination.
- Persistent, inconsolable crying lasting ≥ 3 hours, occurring within 48 hours of vaccination.
- Convulsions with or without fever, occurring within 3 days of vaccination.

In children with progressive neurological disorders, including infantile spasms, uncontrolled epilepsy or progressive encephalopathy, it is better to defer pertussis (Pa or Pw) immunisation until the condition is corrected or stable. However, the decision to give pertussis vaccine must be made on an individual basis after careful consideration of the risks and benefits.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of anaphylactic reactions following the administration of the vaccine.

BOOSTRIX® should be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects. Firm pressure should be applied to the injection site (without rubbing) for at least two minutes.

A history or a family history of convulsions and a family history of an adverse event following DTP vaccination do not constitute contra-indications.

Human Immunodeficiency Virus (HIV) infection is not considered a contraindication for diphtheria, tetanus and pertussis (whole-cell or acellular) immunisation. However in patients with immunodeficiency or in patients receiving immunosuppressive therapy, an adequate immunologic response may not be achieved. In these patients, when tetanus vaccine is needed for tetanus prone wound, plain tetanus vaccine should be used.

Extremely rare cases of collapse or shock-like state (hypotonic-hyporesponsiveness episode) and convulsions within 2 to 3 days of vaccination have been reported in DTPa and DTPa combination vaccines.

Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from faints.

As with any vaccine, a protective immune response may not be elicited in all vaccinees.

INTERACTIONS

Concomitant use with other inactivated vaccines and with immunoglobulin is unlikely to result in interference with the immune responses.

When considered necessary, BOOSTRIX® can be administered simultaneously with other vaccines or immunoglobulins.

If BOOSTRIX® is to be given at the same time as another injectable vaccine or immunoglobulin, the products should always be administered at different sites.

BOOSTRIX™ must not be mixed with other vaccines.

Use In Pregnancy (Category B2)

Adequate human data on use during pregnancy and adequate animal reproduction studies are not available. Therefore, BOOSTRIX™ should be used during pregnancy only when clearly needed, and the possible advantages outweigh the possible risks for the foetus. When protection against tetanus is sought, consideration should be given to tetanus or combined diphtheria-tetanus vaccines. As with all inactivated vaccines, one does not expect harm to the foetus.

Use In Lactation

The safety of BOOSTRIX® when administered to breast-feeding women has not been evaluated.

It is unknown whether BOOSTRIX® is excreted in human breast milk.

BOOSTRIX® should only be used during breast-feeding when the possible advantages outweigh the potential risks.

Effects on the ability to drive and use machines

The vaccine is unlikely to produce an effect on the ability to drive and use machines.

ADVERSE REACTIONS

Clinical Trial Experience

The safety profile below is based on data from clinical trials where BOOSTRIX® was administered to 839 children (from 4 to 9 years of age) and 1931 adults, adolescents and children (above 10 years of age).

Adverse reactions reported are listed according to the following frequency:

Very common: $\geq 1/10$

Common: $\geq 1/100$ and $< 1/10$

Uncommon: $\geq 1/1000$ and $< 1/100$

Rare: $\geq 1/10,000$ and $< 1/1000$

Very rare: $< 1/10,000$

Children from 4 to 9 years of age

Infections and infestations

Uncommon: upper respiratory tract infection

Metabolism and nutrition disorders

Common: anorexia

Psychiatric disorders

Very common: irritability

Nervous system disorders

Very common: somnolence

Common: headache

Uncommon: disturbances in attention

Eye disorders

Uncommon: conjunctivitis

Gastrointestinal disorders

Common: diarrhoea, vomiting, gastrointestinal disorders

Skin and subcutaneous tissue disorders

Uncommon: rash

General disorders and administration site conditions

Very common: injection site reactions (including pain, redness and swelling), fatigue

Common: fever ≥ 37.5 °C (including fever > 39 °C),

Uncommon: other injection site reactions (such as induration), pain

Adults, adolescents and children from the age of 10 years onwards

Infections and infestations

Uncommon: upper respiratory tract infection, pharyngitis

Blood and lymphatic system disorders

Uncommon: lymphadenopathy

Nervous system disorders

Very common: headache

Common: dizziness

Uncommon: syncope

Respiratory, thoracic and mediastinal disorders

Uncommon: cough

Gastrointestinal disorders

Common: nausea, gastrointestinal disorders

Uncommon: diarrhoea, vomiting

Skin and subcutaneous tissue disorders

Uncommon: hyperhidrosis, pruritus, rash

Musculoskeletal and connective tissue disorders

Uncommon: arthralgia, myalgia, joint stiffness, musculoskeletal stiffness

General disorders and administration site conditions

Very common: injection site reactions (including pain, redness and swelling), fatigue, malaise

Common: fever ≥ 37.5 °C, injection site reactions (such as injection site mass and injection site abscess sterile)

Uncommon: fever > 39 °C, influenza like illness, pain

Post-marketing experience

Blood and lymphatic system disorders

Rare: angioedema

Immune system disorders

Very rare: allergic reactions, including anaphylactic and anaphylactoid reactions

Nervous system disorders

Rare: convulsions (with or without fever)

Skin and subcutaneous tissue disorders

Rare: urticaria

General disorders and administration site conditions

Rare: extensive swelling of the vaccinated limb, asthenia

Data on 146 subjects suggest a small increase in local reactogenicity (pain, redness, swelling) with repeated vaccination according to a 0, 1, 6 months schedule in adults (> 40 years of age).

Subjects fully primed with 4 doses of DTPw followed by a BOOSTRIX dose around 10 years of age show an increase of local reactogenicity after an additional BOOSTRIX® dose administered 10 years later.

DOSAGE AND ADMINISTRATION

All parenteral drug and vaccine products should be inspected visually for any particulate matter or discolouration prior to administration. Before use of BOOSTRIX™, the vaccine should be well shaken to obtain a homogenous turbid suspension. Discard the vaccine if it appears otherwise.

Dosage

Each dose consists of a 0.5mL ready to use sterile suspension.

Administration

BOOSTRIX™ is administered by deep intramuscular injection, preferably in the deltoid region. THE VACCINE SHOULD NEVER BE ADMINISTERED INTRAVENOUSLY.

This product is for use by one patient on a single occasion. Any unused product or waste material should be disposed of in accordance with local requirements.

Immunisation Schedule

BOOSTRIX™ can be given in accordance with the current local medical practices for booster vaccination with adult-type combined diphtheria-tetanus vaccine, when a booster against pertussis is desired.

Repeat vaccination against diphtheria, tetanus and pertussis should be performed at intervals as per official recommendations (generally 10 years).

BOOSTRIX® can be used in the management of tetanus prone injuries in persons who have previously received a primary vaccination series of tetanus toxoid vaccine. Tetanus immunoglobulin should be administered concomitantly in accordance with official recommendations.

OVERDOSAGE

Cases of overdose have been reported during post-marketing surveillance. Adverse events following overdose, when reported, were similar to those reported with normal vaccine administration.

STORAGE

BOOSTRIX™ should be stored at +2°C and +8°C. DO NOT FREEZE, discard if vaccine has been frozen. The expiry date of the vaccine is indicated on the label and packaging.

PRESENTATIONS

BOOSTRIX™ is presented as a turbid white suspension in a glass vial or glass prefilled syringe. Upon storage a white deposit and clear supernatant can be observed.

The vials and prefilled syringes are made of neutral glass type I, which conforms to European Pharmacopoeia Requirements.

MEDICINE CLASSIFICATION

Prescription Only Medicine

Package Quantities

Syringes: Single dose in packs of 1 or 10

Name and Address

GlaxoSmithKline NZ Ltd
AMP Centre
Cnr Albert & Customs Street
Private Bag 106600
Downtown
Auckland
NEW ZEALAND

ph (09) 367 2900
fax (09) 367 2910

Date of Preparation

25 February 2011

Version: 3.0